G Lübben

No ORCID on file · 5 papers in corpus · active 1996-2001

Study types

  • article 4
  • other 1

Condition tags

  • endometriosis 5
  • dysmenorrhea 3
  • dyspareunia 3
  • chronic_pelvic_pain 2
  • infertility 2
article 2001
Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology ·doi:10.1080/gye.15.3.202.209

Endometriosis is thought to be an ovarian-dependent benign disease that affects up to 12% of women during their reproductive life. For the past ten years the gonadotropin-releasing hormone (GnRH)-agonists have been proved effective and safe…

article 2001
Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis
·doi:10.1080/713602841

Endometriosis is thought to be an ovarian-dependent benign disease that affects up to 12% of women during their reproductive life. For the past ten years the gonadotropin-releasing hormone (GnRH)-agonists have been proved effective and safe…

article 2000
Comparison of leprorelin vs. lynestrenol in patients with endometriosis
·doi:10.1016/s0020-7292(00)80617-7
other 1998
[What is the value of combined surgical-hormonal therapy of endometriosis management?]
Zentralblatt fur Gynakologie

Medical oestrogen suppressive therapy has to be considered as an important principle in the management of endometriosis. In the last years GnRHa became the "gold standard" as pre or postoperative measures before/after surgical intervention.…

article 1996
[Results of long-term follow-up in treatment of endometriosis with the GnRH agonist leuprorelin acetate depot (Enantone-Gyn monthly depot)].
Zentralblatt fur Gynakologie

In a previous study 198 patients with histologically confirmed endometriosis underwent a "three-step" therapy, where surgical removal of endometriosis implants was followed by a 6 months treatment with 3.75 mg leuprorelinacetate depot as mo…